Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Mar 3:5:25.
doi: 10.1186/1471-2407-5-25.

Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1

Affiliations

Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1

Vasilis Karavasilis et al. BMC Cancer. .

Abstract

Background: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets.

Methods: Paraffin embedded archival material from 81 patients diagnosed with CUP was used. Tumor histology was adenocarcinoma (77%), undifferentiated carcinoma (18%) and squamous cell carcinoma (5%). The tissue expression of CD34, VEGF and TSP-1 was assessed immunohistochemically by use of specific monoclonal antibodies and was analyzed against clinicopathological data.

Results: VEGF expression was detected in all cases and was strong in 83%. Stromal expression of TSP-1 was seen in 80% of cases and was strong in 20%. The expression of both proteins was not associated with any clinical or pathological parameters. Tumor MVD was higher in tumors classified as unfavorable compared to more favorable and was positively associated with VEGF and negatively with TSP-1.

Conclusion: Angiogenesis is very active and expression of VEGF is almost universal in cancers of unknown primary. These findings support the clinical investigation of VEGF targeted therapy in this clinical setting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival curve of 81 CUP patients analyzed
Figure 2
Figure 2
High-density of neoplastic vessels highlighted by stained anti-CD34 antibody in a case of a poorly differentiated adenocarcinoma of unknown primary (Original magnification 200, counterstained with hematoxylin).
Figure 3
Figure 3
Strong cytoplasmic immunohistochemical staining of tumor cells for VEGF in a CUP case. It is shown the characteristic granular cytoplasmic staining pattern and the occasionally weak positive reaction of intervening stromal and endothelial cells (original magnification ×200, counterstained with hematoxylin)
Figure 4
Figure 4
Diffuse strong immunoreactivity of extracellular matrix for TSP-1 adjacent to neoplastic cell population in a CUP case. (Original magnification ×400, counterstained with hematoxylin)

Similar articles

Cited by

References

    1. Briasoulis E, Pavlidis N. Cancer of Unknown Primary Origin. Oncologist. 1997;2:142–152. - PubMed
    1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990–2005. doi: 10.1016/S0959-8049(03)00547-1. - DOI - PubMed
    1. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol. 2003;14:191–196. doi: 10.1093/annonc/mdg068. - DOI - PubMed
    1. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309. - PubMed
    1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803. doi: 10.1038/nrc909. - DOI - PubMed

MeSH terms